By Application
Hot products 
-
Mouse Anti-AMACR Recombinant Antibody (CB34A) (CBMAB-CA034LY)
-
Rat Anti-EPO Recombinant Antibody (16) (CBMAB-E1578-FY)
-
Mouse Anti-CD59 Recombinant Antibody (CBXC-2097) (CBMAB-C4421-CQ)
-
Rabbit Anti-ABL1 (Phosphorylated Y185) Recombinant Antibody (V2-443434) (PTM-CBMAB-0001YC)
-
Mouse Anti-BIRC3 Recombinant Antibody (315304) (CBMAB-1214-CN)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
-
Armenian hamster Anti-CD40 Recombinant Antibody (HM40-3) (CBMAB-C10365-LY)
-
Rat Anti-CD300A Recombinant Antibody (172224) (CBMAB-C0423-LY)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
-
Mouse Anti-ATP1B3 Recombinant Antibody (1E9) (CBMAB-A4021-YC)
-
Rat Anti-CD34 Recombinant Antibody (MEC 14.7) (CBMAB-C10196-LY)
-
Mouse Anti-BIRC7 Recombinant Antibody (88C570) (CBMAB-L0261-YJ)
-
Mouse Anti-CFL1 (Phospho-Ser3) Recombinant Antibody (CBFYC-1770) (CBMAB-C1832-FY)
-
Mouse Anti-AMOT Recombinant Antibody (CBYC-A564) (CBMAB-A2552-YC)
-
Rabbit Anti-CAMK2A Recombinant Antibody (BA0032) (CBMAB-0137CQ)
-
Rabbit Anti-BRCA2 Recombinant Antibody (D9S6V) (CBMAB-CP0017-LY)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Mouse Anti-CALR Recombinant Antibody (CBFYC-0763) (CBMAB-C0818-FY)
-
Mouse Anti-BMI1 Recombinant Antibody (CBYC-P026) (CBMAB-P0108-YC)
-
Mouse Anti-CASP7 Recombinant Antibody (10-01-62) (CBMAB-C2005-LY)
Carcinoid
Fig.1 Carcinoid
Carcinoid (also carcinoid tumor) is a slow-growing type of neuroendocrine tumor developing from the cells of the neuroendocrine system. The tumors of the midgut (jejunum, ileum, cecum and appendix) are related to carcinoid syndrome. Carcinoid tumors overwhelmingly show as malignant tumor of the appendix, but they are most commonly related to the small intestine, and they can also be found in the stomach and rectum. They are considered to grow in the liver, but this finding is normally a display of metastatic disease from a primary carcinoid occurring somewhere in the body. They have a very mind growth rate compared to most malignant tumors. The median age at diagnosis for all patients with neuroendocrine tumors is 63 years. As the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with MRI or CT, labs for tumor markers such as serotonin can be applied.
Loading...
Compare
